logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's VPRIV Shows Improvement In Gaucher-Related Bone Disease - Quick Facts

Shire plc (SHP.L,SHPGY) reported new data that demonstrate velaglucerase alfa for injection or VPRIV, the company's enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients. The data presented show that VPRIV improves Gaucher-related bone disease by a sustained increase in bone mineral density or BMD.

Results from a head-to-head Phase III study of VPRIV and Cerezyme, and follow-on extension trial of VPRIV, show a statistically significant improvement in lumbar spine BMD in Gaucher patients starting at nine months of treatment with VPRIV. Clinically and statistically significant improvement from baseline in mean LS Z-score was witnessed at 9 months of treatment with VPRIV, but not in the cohort of patients treated with Cerezyme.

In Gaucher disease patients, BMD is generally reduced compared to individuals without Gaucher disease, often resulting in lower Z-scores.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following his twelve-day trip to Asia, President Donald Trump announced Monday the U.S. is putting North Korea back on a list of state sponsors of terrorism. Trump announced the move in comments ahead of a Cabinet meeting and said his administration would also be ramping up sanctions on North Korea. Volkswagen plans to invest about 22.8 billion euros in its core brand from 2018 to 2022, with main focus on e-mobility and modularization. In a statement on Saturday, the German automaker announced that the investments, as part of the brand's Transform 2025+ strategy, will significantly boost the brand's largest product and technology offensive. Health IQ Insurance Services, a startup focused on providing life insurance for health-conscious individuals, said it has secured $34.6 million in Series C funding, led by Andreessen Horowitz. To date, the company has raised a total of $81 million in funding mostly from its existing investors.
comments powered by Disqus
Follow RTT